LD-2 disclosure · 2nd Quarter - Amendment
ALLIANCE FOR AGING RESEARCH
Client
- Location
- District of Columbia · United States of America
Registrant
- Description
- Non-profit healthcare advocacy organization
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
3 issuesBudget/Appropriations
-FY27 report language for the Food and Drug Administration on antipsychotics black box warning -FY27 report language for the Medicare Program antipsychotics measure -FY27 report language for the Medicare Prescription Payment Plan -FY27 report language for utilization management reform in the Medicare program -FY27 medical research funding -FY27 funding for FDA's Neurology Drug Program -FY 27 Appropriations H.R. 9260 and pending Senate bill, Increase Funding for Programs benefitting older adults at HHS, including ASPE, NIH, CDC HRSA, ARHQ, FDA, CMS, ACL
Lobbyistsms ADINA ROSE LASSER · SCOTT FREY
Covered position (SCOTT FREY): Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy
TargetedSENATE · HOUSE OF REPRESENTATIVES
Health Issues
-Alzheimer's Screening & Prevention Act (ASAP) H.R. 6130/ S. 3267 -Lowering Costs for Caregivers Act (S. 1565/H.R. 138) -Federal vaccine messaging -Impacts of IRA on Older Americans -National Institutes of Health advance funding of multi-year research grants -Clinical Trials Modernization Act H.R.7905 -Patient Access to Cancer and Complex Therapies Act H.R. 4299 -Diabetes Foot Health and Modernization Access Act H.R. 7905 -Oppose PBM Kickbacks H.R. 7895 -Oppose Codification of MFN Drug Pricing Proposals (no bill) -End Coverage with Evidence Development for Alzheimer's medications and Trans Catheter Aortic Valve Replacement
Lobbyistsms ADINA ROSE LASSER · SCOTT FREY
Deputy Commissioner for Legislation and Congressional Affairs -- SSA, Chief of Staff -- SSA, Senior Strategic Advisor -- Office of National Drug Control Policy